Prof. Dr Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Essen, Germany and until recently acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Los Angeles, California, USA. 

In 2011, he completed his residency in nuclear medicine at Klinikum rechts der Isar, Technische Universität München, Munich, Germany, focusing on his research entitled “In Vivo Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology”. Following this, Prof. Dr Herrmann then went onto complete a fellowship at Hokkaido University, Hokkaido, Japan, and received an executive MBA degree from the University of Zürich, Zürich, Switzerland. From 2012 to 2016, he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg, Würzburg, Germany. Until 2023, he served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. 

Presently, he is Section Editor of The Journal of Nuclear Medicine and Imaging Editor of European Urology. He has also authored more 700 peer-reviewed articles. 

Prof. Ken Herrmann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Ken Herrmann reported receiving consultant fees from Advanced Accelerator Applications, a Novartis company, Actithera, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, MSD, Molecular Partners, NVision, POINT Biopharma, Pentixapharm, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, ymabs, receiving research grants from Advanced Accelerator Applications, a Novartis company, Boston Scientific, Janssen, having stock or other ownership interests with AdvanCell, Aktis Oncology, Convergent, NVision, Sofie Biosciences and Yellowbird Diagnostics.